Alcidion Group Ltd (ASX:ALC) is acquiring Telstra Health’s Kyra patient flow products business in a deal that materially expands the healthcare software-as-a-service (SaaS) group’s footprint across Australian hospitals and deepens its exposure to one of the sector’s most persistent operational problems — managing patient movement through overcrowded health systems.
The ASX-listed company has agreed to pay an up-front $3 million for the Kyra Patient Flow Manager, Kyra Queue Manager and Kyra IQ products, with a further earn-out of up to $1 million tied to future recurring revenue targets.
Alcidion said the acquisition would strengthen its position as a provider of enterprise patient flow solutions across Australia, New Zealand and the UK, while adding around 33 long-standing customers across public and private hospitals.
The Kyra suite is forecast to generate FY26 revenue of about $3.7 million, with more than 90% tied to recurring product revenue and underlying EBITDA of roughly $1.1 million.
Importantly for Alcidion, only two of Kyra’s existing customers already overlap with its own customer base, creating what the company sees as a sizeable cross-selling opportunity for its broader Miya Precision platform.
The acquisition also gives Alcidion a much larger presence in Queensland, where Kyra’s products are already used by most hospital and health services.
Hospital bottlenecks create growing demand
Managing director and CEO Kate Quirke described the deal as both strategically and financially aligned with Alcidion’s broader push to build a larger recurring revenue healthcare software business.
“This acquisition is highly complementary to our core business and further consolidates our market position in the Australian patient flow market. There is strong strategic and financial alignment as we continue to build a scaled, recurring revenue-driven health technology company,” Quirke said.
“Patient flow continues to be a critical pain point across the healthcare setting with an ageing population and increasing rates of hospital admission expected to only further compound the need for validated enterprise digital solutions that both simplify decision support and also remove administrative burden,” she added.
Expanding a broader healthcare platform
The acquisition builds on what has already been a strong period of contract growth and expansion for Alcidion.
The company recently reported record first-half FY26 revenue of $25.5 million, up 44% year-on-year, alongside underlying EBITDA of $4.2 million and annual recurring revenue of $31.1 million.
Its Miya Precision platform is now deployed across more than 400 hospitals globally, supporting more than 50,000 hospital beds and 130,000 active users across Australia, New Zealand and the UK.
The platform focuses heavily on hospital workflow, interoperability and operational visibility — areas increasingly attracting investment from health systems trying to reduce bottlenecks, ambulance ramping and discharge delays.
Alcidion’s patient flow capabilities sit alongside broader modules covering clinical communications, electronic observations, virtual care, integrated care records and AI-enabled documentation tools.
The company has also been expanding internationally, particularly within the UK NHS market, where it recently secured a preferred supplier position for a new electronic patient record platform at University Hospitals Sussex.
AI and operational efficiency emerging as key themes
The Kyra acquisition also aligns with Alcidion’s increasing emphasis on operational intelligence and AI-driven clinical workflows.
In its February FY26 results presentation, the company highlighted a growing suite of AI-enabled products within Miya Precision, including generative AI tools for clinical documentation, summarisation and problem detection.
Alcidion said those capabilities were designed to reduce clinician administrative burden while improving decision-making and data quality across complex healthcare environments.
The company’s broader strategy continues to focus on expanding within existing markets, adding new modules into existing customer environments and selectively pursuing acquisitions that increase market share or product capability.
The Kyra acquisition is expected to complete by the end of June 2026 and will be funded from existing cash reserves. Alcidion held $15.1 million in cash and no debt at the end of March.